U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
Reuters Health Information Logo

Nasal spray may trigger migraine

Printer-friendly version E-mail this page to a friend

Reuters Health

Monday, March 2, 2009

NEW YORK (Reuters Health) - People with hay fever -- more accurately termed allergic rhinitis -- may find themselves with a migraine after they use a nasal steroid spray to relieve their stuffy noses.

Dr. Jitka Pokladnikova, of Charles University in Prague, and colleagues reviewed the World Health Organization's global database and other sources and found an unexpected cluster of 38 cases of migraine suspected to be related to the use of intranasal corticosteroids.

The suspected intranasal corticosteroids included six different drugs: fluticasone, beclomethasone, budesonide, mometasone, flunisolide, and triamcinolone. In 24 cases the intranasal corticosteroid was the only drug used, the researchers report in the medical journal Cephalalgia.

Re-exposure to the intranasal corticosteroid led to a relapse of migraine in eight patients. None of the drugs exceeded the maximum daily recommended dose range in any reported case.

In the 16 reports where time to onset was recorded, migraine developed early in the course of intranasal corticosteroid treatment in 12 cases -- within the first four days.

A connection between allergic rhinitis and migraine has already been established. The new findings suggest that, "in addition, intranasal corticosteroids might cause or worsen migraine or migraine-like headache," Pokladnikova and colleagues conclude.

SOURCE: Cephalalgia, March 2009.


Reuters Health

© 2009 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies. For additional information on other Reuters media services please visit http://about.reuters.com/media/.


More News on this Date

Related MedlinePlus Pages: